Results 181 to 190 of about 86,485 (257)

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, Volume 78, Issue 10, Page 1317-1323, October 2026.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Tocilizumab for critically ill patients with refractory anti-NMDAR encephalitis: a case report. [PDF]

Front Immunol
Lima RP, Ferreira JHF, Fujino MVT, de Araújo ALV, da Silva MEN, Dutra LA.   +5 more
europepmc   +1 more source

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8847-8860, October 2026.
ABSTRACT Aims Cardiovascular autonomic neuropathy (CAN) is a severe form of diabetic neuropathy affecting approximately one in five people with diabetes and is a major predictor of cardiovascular mortality. Low‐grade inflammation may contribute to CAN development, but the exact inflammatory factors associated with CAN remain unclear.
Michelle Damgaard, Marietta Kokla, Rebekka H. Gerwig, Hatice Isik Mizrak, Sofie Korsgaard Hecquet, Tik Muk, Gurjeet Kaur, Birgitte Brock, Christian Stevns Hansen, Joachim Størling   +9 more
wiley   +1 more source

Long-term survival with tocilizumab treatment for tislelizumab-related pneumonitis in a patient with non-small cell lung cancer: A case report. [PDF]

Oncol Lett
Yu L, Guo QM, Liu L, Wang Y, Chen F, Zhang XT.   +5 more
europepmc   +1 more source

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

European Journal of Haematology, Volume 117, Issue 4, Page 922-935, October 2026.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio, Antonio José Martinez‐Mellado, Jonathan Kiwitt‐Cárdenas, José G. Clavel, Bartolomé García‐Perez, Pedro Castro, Maribel Diaz‐Ricart, Andrés Carrillo‐Alcaraz, Amparo López‐Bernús, Enrique Bernal Morell, Aychel Roura, Sonia Marín, Francisco‐José Ruiz‐López, Elena Solana‐Martinez, Domingo Martinez‐Baño, Carlos L. Albacete Moreno, Enriqueta Andreu Soler, Adrián Tellez Santoyo, Sara Fernández Méndez, Jose A. Noguera Velasco, Iria Cebreiros Lopez, Andrés Parrilla, Alberto Espuny‐Miró, David García‐Bernal, Miguel Blanquer, Andrés Sánchez‐Salinas, Francisca Iniesta, Cristina Hernandez Garcia, Manuel Muro, Alfredo Minguela Puras, Antonio Moreno‐Docón, Alberto M. Torres‐Cantero, Maria Munoz Garcia, Manuel Serrano, Massimo Iacobelli, Carmelo Carlo‐Stella, Lee‐Jen Wei, Paul G. Richardson, José M. Moraleda   +38 more
wiley   +1 more source

<i>Candida oesophagitis</i> as an Initial Manifestation of VEXAS Syndrome: Expanding Evidence for an Acquired Immunodeficiency Phenotype. [PDF]

EJHaem
Vintges DR, Weerheim M, Karim F.
europepmc   +1 more source

Tocilizumab for severe and refractory mucous membrane pemphigoid

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1682-1691, October 2026.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt, Maud Maho‐Vaillant, Julie Gueudry, Marie‐Laure Golinski, Marion Marcaillou, Blanche Bergeret, Guillaume Chambon, Pierre Bouchetemble, Soumeya Bekri, Abdellah Tebani, Hervé Maillard, Cécile Morice, Anais Vautier, Edgar‐Pierre Libert, Christelle Le Roux‐Villet, Marion Carrette, Olivier Boyer, Vivien Hébert, Sébastien Calbo, André Gillibert, Pascal Joly   +20 more
wiley   +1 more source

Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial.

JAMA Psychiatry
Foley ÉM, Turner N, Margelyte R, Jones HJ, Kaser M, Lewis G, Jones PB, Khandaker GM.   +7 more
europepmc   +1 more source

Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey. [PDF]

Rheumatol Adv Pract
Lakin KS, Valenzuela A, Pauling JD, Jannat-Khah DP, Gripp K, Golam O, Domsic RT, Spiera RF, Gordon JK.   +8 more
europepmc   +1 more source